The 20 Best Midline Lethal Granuloma Doctors Near Me

Emmanouil Alimpertis is a Hematologist and an Oncologist in Marinette, Wisconsin. Dr. Alimpertis is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET), Neuroendocrine Tumor, Familial Prostate Cancer, Prostate Cancer, and Splenectomy.

Dong Li practices in Beijing, China. Mr. Li is rated as an Elite expert by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Midline Lethal Granuloma, Necrosis, and Psoriasis.

. Dr. Osterhus is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Anaplastic Thyroid Cancer, Thyroid Cancer, Follicular Thyroid Cancer, Laryngectomy, and Septoplasty.

Dr. Kyle Work joined the Cancer Centers of Colorado at St. Mary?s Medical Center oncology team in 2018. He is a hematologist-oncologist. Dr. Work treats all types of cancers with a special interest in head and neck cancer, lung cancer and genitourinary cancers.Dr. Work is originally from Tulsa, Oklahoma where he graduated from the University of Tulsa with a degree in biology, and earned his medical degree at Oklahoma State University. He then moved to Kansas City where he completed his internal medicine residency and hematology / oncology fellowship at the University of Kansas Health System. During his hematology and oncology fellowship, he served as chief fellow for two years.Dr. Work is an investigator involved in clinical research trials in the area of hematology and medical oncology. His clinical research focus includes head and neck cancers, brain and lung cancers. When he is not working, he enjoys mountain biking, camping, and hiking with his wife and golden retrievers. Dr. Work is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, EGFR Positive Lung Cancer, and Squamous Cell Lung Carcinoma.

Richard F. Ambinder, M.D., Ph.D., currently serves as the James B. Murphy Professor of Oncology and the Director of the Division of Hematologic Malignancies at the Johns Hopkins Kimmel Cancer Center. He is program co-leader of the Hematologic Malignancies and Bone Marrow Transplantation Program and leads the AIDS Malignancy Consortium (AMC) site at Johns Hopkins and the AMC Translational Sciences Working Group nationally. Dr. Ambinder graduated from Harvard College with a Bachelor’s degree in biochemistry, after which he received his medical degree from the Johns Hopkins University School of Medicine before completing his residency at the Johns Hopkins Hospital. He also earned his Ph.D. in pharmacology from the Johns Hopkins University, and completed his oncology fellowship at Johns Hopkins. Within the clinic, Dr. Ambinder is active in the treatment of lymphoma and Kaposi’s sarcoma. Dr. Ambinder’s research is focused on exploring opportunities to prevent or treat cancer with viral infections. Virus-associated tumors are among the most common malignancies in certain populations and regions. For instance, Burkitt's lymphoma (EBV) and Kaposi's sarcoma (KSHV) are common in equatorial Africa, nasopharyngeal carcinoma (EBV) is common in southern Chinese populations or those with southern Chinese origins, and immunoblastic lymphomas (EBV) are common in immunocompromised patients (organ transplant recipients, AIDS patients, etc). Thus, Dr. Ambinder’s new approaches to prevention, diagnosis, and treatment stand to have a direct impact on the lives of cancer patients around the globe. Additionally, the study of how viruses can impact these tumors is important in creating model systems for the development of new approaches to cancer care. Currently, many immunotherapies target unidentified antigens, making the measurement of relevant immune responses problematic at best. However, in EBV-associated tumors the antigens are well defined, thus allowing the Ambinder lab to define the epitope-specific cellular immune responses. As a result of this breakthrough, interventions designed to alter immune response —whether they be vaccine based interventions, adoptive immunotherapy interventions, or pharmacologic interventions — may all be assessed in terms of relevant surrogate markers. Much in the same way the treatment of Hodgkin's lymphoma with radiotherapy and chemotherapy paved the way for the modern approach to cancer treatment more broadly, the treatment of EBV-associated tumors (including Hodgkin's lymphoma) may pave the way to the more generalized use of these modalities to treat a myriad of cancer types. Dr. Ambinder is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, Tissue Biopsy, and Bone Marrow Aspiration.

Jeffrey Thomas is a Hematologist and an Oncologist in Athens, Georgia. Dr. Thomas is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Midline Lethal Granuloma, Iron Deficiency Anemia, Essential Thrombocythemia, and Breast Cancer. Dr. Thomas is currently accepting new patients.

Triple board-certified in internal medicine, hematology and medical oncology, Dr. Mohamad Cherry is medical director of Hematology at Atlantic Health System. He joins Atlantic Hematology Oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center, bringing years of clinical knowledge and expertise.With specialty training from some of the nation's most skilled clinicians, Dr. Cherry attained some of his clinical training at the leukemia department at MD Anderson and his fellowship in hematology/oncology from the University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He performed two residencies - an internal medicine residency at Staten Island University Hospital and a laboratory medicine residency at the American University of Beirut Medical Center in Lebanon. Previously, Dr. Cherry attained his medical degree at Lebanese University and performed his internship at Sacre Coeur Hospital-Lebanese University. He also earned a master of science degree in clinical and translational research from University of Oklahoma College of Public Health.Dr. Cherry remains on staff as clinical associate professor of hematology/oncology at University of Oklahoma Health Sciences Center's Stephenson Cancer Center. He is also the director of its hematology/oncology fellowship program and co-chairs the Academy of Teaching Scholars Faculty Development, Education and Mentoring Committee. Other administrative roles include co-chair of the leukemia working group at the Sarah Cannon Research Institute Blood Cancer Consortium.As a principal investigator of multiple clinical trials, Dr. Cherry has performed groundbreaking research in niche areas that include epigenetics and development of new therapeutics in relapsed and refractory blood cancers. He has developed teaching materials and book chapters, and has lectured both nationally and internationally.Dr. Cherry continues to serves as a mentor and an advisor to fellows, residents and medical students. He contributes to continuing education, public health, and professional development, and has won awards and funding for both his research and his clinical pursuits. Dr. Cherry is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Acute Myeloblastic Leukemia without Maturation, Midline Lethal Granuloma, and Bone Marrow Aspiration.

. Dr. Scanlon is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. Her top areas of expertise are Colonic Malakoplakia, Pleural Effusion, Pleurisy, and Subcutaneous Emphysema.

. Dr. Farwell is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Mesenchymoma, and Myxoid Liposarcoma.

. Dr. Pantel is rated as an Experienced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Neuroendocrine Tumor, Classical Hodgkin Lymphoma, Lung Nodules, Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL), and Liver Embolization.

John Plastaras is a Radiation Oncologist in Philadelphia, Pennsylvania. Dr. Plastaras is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Hodgkin Lymphoma, T-Cell Lymphoma, Mediastinal Tumor, and Midline Lethal Granuloma. Dr. Plastaras is currently accepting new patients.

Ara Chalian is an Otolaryngologist in Philadelphia, Pennsylvania. Dr. Chalian is rated as a Distinguished provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Salivary Gland Tumors, Acinic Cell Carcinoma of Salivary Glands, Tongue Cancer, Thyroidectomy, and Gastrostomy. Dr. Chalian is currently accepting new patients.

Kanwaldeep Rasila is an Oncologist in Fairfield, California. Dr. Rasila is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. Her top areas of expertise are Pleuropulmonary Blastoma, Lung Cancer, Intraductal Papilloma, and Subacute Combined Degeneration. Dr. Rasila is currently accepting new patients.

Akash Mukherjee is a Hematologist and an Oncologist in Cincinnati, Ohio. Dr. Mukherjee is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Diffuse Large B-Cell Lymphoma (DLBCL), Large-Cell Immunoblastic Lymphoma, Chronic Myelomonocytic Leukemia (CMML), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Mukherjee is currently accepting new patients.

Seyfettin Alpdogan is an Oncologist in Philadelphia, Pennsylvania. Dr. Alpdogan is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Cutaneous T-Cell Lymphoma (CTCL), Multiple Myeloma, and Bone Marrow Aspiration. Dr. Alpdogan is currently accepting new patients.

Sirisha Jain, MD, is a board-certified hematologist/oncologist with Harrison HealthPartners. Dr. Jain's goal is to, in this time of rapid growth of oncology treatments, with new research being published weekly, incorporate the latest treatments into her practice and stay current on the research. She hopes to form a partnership with her patients where she can help them navigate the information and difficult choices a cancer diagnosis brings. Dr. Jain believes it is vital for the health of her patients to focus on treating the whole person and not just the cancer diagnosis. Dr. Jain is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. Her top areas of expertise are Angiosarcoma, Paget Disease of the Breast, Inflammatory Breast Cancer, Myelodysplastic Syndrome (MDS), and Bone Marrow Aspiration.

Jihua Cheng is a Hematologist Oncology provider in Harrisburg, Pennsylvania. Dr. Cheng is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Childhood Iron Deficiency Anemia, Iron Deficiency Anemia, Anemia, and Pulmonary Embolism.

Erik Cohen, MD, FACS Erik Cohen, MD is the Medical Director of Head and Neck Oncologic Surgery at Morristown Medical Center and is also Clinical Director of the Leonard B Khan Head and neck Cancer Institute at Morristown Medical Center's Carol G. Simon Cancer Center. He is trained in Otolaryngology-Head and Neck Surgery (ear, nose, and throat surgery) and fellowship trained in Head and Neck Oncologic Surgery.Dr. Cohen manages patients with benign and malignant head neck tumors of the head and neck. This includes cancers of the mouth, throat, larynx and HPV-associated oropharynx cancer. He also specializes in management of benign and malignant tumors of the thyroid and parathyroid glands, salivary gland surgery including parotidectomy with facial nerve preservation, nasal cavity and paranasal sinus tumors, complex skin cancer surgery, and skull base surgery. He is experienced in minimally invasive approaches, including transoral robotic surgery (TORS) as well as endoscopic CO2 laser surgery.Dr. Cohen attended Medical School at the Albert Einstein College of Medicine in New York. He completed his residency training in Otolaryngology-Head and Neck Surgery at Temple University Hospital in Philadelphia, and a fellowship in Head and Neck Oncologic Surgery at Memorial Sloan Kettering Cancer Center in New York City. He was a faculty member at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School prior to joining Morristown Medical Center and the Atlantic Health System in 2012. He is a past president of the New York Head and Neck Society and an active member of several professional societies. Dr. Cohen is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Acinic Cell Carcinoma of Salivary Glands, Salivary Gland Tumors, Laryngeal Cancer, Thyroidectomy, and Gastrostomy.

I enjoy reading, visiting with my grandkids, fishing, watching sports, and paying attention to my loving wife. Dr. Stanek is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Myelodysplastic Syndrome (MDS), Gastric Lymphoma, Non-Hodgkin Lymphoma, Large-Cell Immunoblastic Lymphoma, and Bone Marrow Aspiration.

"Joseph Rosales, MD, has been a physician for over 20 years and a hematologist-oncologist in Western Washington since 2011 -- in Seattle, Federal Way and Tacoma. He is experienced in general hematology and oncology, with specialties in breast and thoracic oncology. Dr. Rosales considers himself a guide in his patients’ therapeutic journey. He meets his patients wherever they are - physically and emotionally - and strives to provide them the knowledge and perspective required to navigate difficult decisions in their care. His treatment philosophy has been consistent: to make sure that the patient remains in as much control of their care as possible while getting the best care possible.Dr. Rosales also maintains activity within the community, including involvement in oncologic education and advocacy. He received the2022 Binaytara Foundation for Excellence in Cancer Care ""Rising Star in Health Equity"" awardfor his demonstration of excellent leadership in improving cancer care in underprivileged communities.Multidisciplinary Lung Cancer Treatment during Covid-19 Video". Dr. Rosales is rated as an Advanced provider by MediFind in the treatment of Midline Lethal Granuloma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Bone Marrow Aspiration.